| Identification | Back Directory | [Name]
Selexipag Metabolite-d6 (ACT-333679-d6) | [CAS]
1265295-56-4 | [Synonyms]
Metabolite-d6
Selexipag metabolite ACT-333679 D6
Selexipag Metabolite-d6 (ACT-333679-d6) | [Molecular Formula]
C25H29N3O3 | [MOL File]
1265295-56-4.mol | [Molecular Weight]
419.53 |
| Hazard Information | Back Directory | [Uses]
MRE-269-d6 is deuterium labeled MRE-269. MRE-269 is an active metabolite of selexipag, and acts as a selective IP receptor agonist. | [References]
[1] Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. DOI:10.1177/1060028018797110
[2] Fuchikami C, et al. A comparison of vasodilation mode among selexipag (NS-304; [2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide]), its active metabolite MRE-269 and various prostacyclin receptor agonists in rat, porcin DOI:10.1016/j.ejphar.2016.11.057
[3] Orie NN, et al. Differential actions of the prostacyclin analogues treprostinil and iloprost and the selexipag metabolite, MRE-269 (ACT-333679) in rat small pulmonary arteries and veins. Prostaglandins Other Lipid Mediat. 2013 Oct;106:1-7 DOI:10.1016/j.prostaglandins.2013.07.003
[4] Kuwano K, et al. A long-acting and highly selective prostacyclin receptor agonist prodrug, 2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide (NS-304), ameliorates rat pulmonary hypertension with unique relaxant responses DOI:10.1124/jpet.108.138305 |
|
|